• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Harvard researchers retract stem cell paper

Harvard researchers retract stem cell paper

October 14, 2010 By MassDevice staff

HSCI logo

Harvard University researchers retracted a paper published in the journal Nature after discovering problems with some of its data, but the study’s lead author refused to sign on to the retraction.

Amy Wagers, a biologist at Harvard’s Stem Cell Institute and the Joslin Diabetes Center, and two of her co-authors signed a statement today pulling the January article "after a re-examination of the publication raised serious concerns with some of the reported data."

"These concerns have undermined the authors’ confidence in the support for the scientific conclusions reported," according to the retraction. "Although this matter is under further review, these authors wish to retract the paper in its entirety, and regret any adverse consequences that may have resulted from the paper’s publication. The retraction has not been signed by [lead author] Shane R. Mayack, who maintains that the results are still valid."

The paper dealt with the aging of stem cells. The problematic data concerned "the role of osteopontin-positive niche cells in the rejuvenation of haematopoietic stem cells in aged mice," according to the retraction.

Joslin spokesman Eric Bender said he could not comment on whether Mayack was still working in the laboratory, according to The Boston Globe. Wagers said in prepared remarks that she immediately notified the Joslin Diabetes Center, Harvard Medical School, and Nature after learning about the problems with the data, according to the newspaper.

"My primary concern has always been to ensure the integrity of the scientific process and my research, and I have taken all appropriate steps to make certain that any errors in the record are fully corrected," Wagers said. "I regret any confusion that has resulted from the publication of this paper and am deeply grateful to my colleagues who are painstakingly working with me to replicate these experiments and evaluate the data."

Filed Under: News Well, Stem Cells Tagged With: Harvard Stem Cell Institute

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy